Deltec Asset Management’s Theravance Biopharma TBPH Stock Holding History

Deltec Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$255K	Buy	+15,000	New	+$248K	0.04%	224

Other funds holding TBPH

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return

Juncture Wealth Strategies Scottsdale, Arizona $384M AUM 27.62% 1-Year Est. Return

Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Thompson Investment Management Madison, Wisconsin $872M AUM 35.59% 1-Year Est. Return

Mirae Asset Global Investments

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Deltec Asset Management's TBPH Position: Q2 2026 in Review

Deltec Asset Management opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 15,000 shares worth $255K. The stake represents 0.04% of the portfolio and ranks #224 among its holdings.

18 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

Deltec Asset Management held 15,000 shares of Theravance Biopharma worth $255K as of Q2 2026.
Theravance Biopharma was a new Deltec Asset Management position in Q2 2026.
Theravance Biopharma made up 0.04% of Deltec Asset Management's portfolio in Q2 2026, its #224 holding.
18 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Deltec Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.